Results 1 to 10 of about 21,108 (240)

Integrated Omics Insights into Dapagliflozin Effects in Sepsis-Induced Cardiomyopathy

Biomolecules
Background: Sepsis-induced cardiomyopathy (SIC) is a life-threatening cardiac complication of sepsis with limited therapeutic options. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has demonstrated cardioprotective effects in heart ...
Weiwei Lai, Li Liu, Shuhang Wang, Yancun Liu, Yanfen Chai   +4 more
doaj   +2 more sources

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

Cardiovascular Diabetology
Background Although several previous studies tested SGLT2 inhibitors in the setting of an acute, non-cardiovascular illness, detailed information on their efficacy and safety among participants with and without type 2 diabetes (T2D) from double-blind ...
Mohammad Abdel Jawad, Remo H. M. Furtado, Russell Esterline, Jan Oscarsson, Samvel B. Gasparyan, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Anna Maria Langkilde, Philip Ambery, Shachi Patel, Kensey Gosch, Sheryl L. Windsor, Ronaldo V. P. Soares, Diogo D. F. Moia, Matthew Aboudara, Ali Javaheri, J. F. Kerr Saraiva, Lilia Nigro Maia, Otavio Berwanger, Andrew J. Sauer, Mikhail N. Kosiborod   +22 more
doaj   +1 more source

Dapagliflozin: A Promising Strategy to Combat Cisplatin-Induced Hepatotoxicity in Wistar Rats

Biology
Recognizing the challenges posed by chemotherapy, specifically the hepatotoxic effects of drugs like cisplatin, this study aimed to examine the hepatoprotective potential of dapagliflozin to mitigate cisplatin-induced hepatotoxicity in a rat model.
Shakta Mani Satyam, Laxminarayana Kurady Bairy, Abdul Rehman, Mohamed Farook, Sofiya Khan, Anuradha Asokan Nair, Nirmal Nachiketh Binu, Mohamed Yehya, Mohammed Moin Khan   +8 more
doaj   +1 more source

Dapagliflozin, Empagliflozin ve Eksenatid Kullanan Tip 2 Diyabetli Hastalarda Kardiyovasküler Olay Oranlarının Retrospektif Olarak Değerlendirilmesi

Uludağ Üniversitesi Tıp Fakültesi Dergisi
Tip 2 diyabet hastalarında kardiyovasküler hastalıklar diyabeti olmayanlara göre daha yüksektir. SGLT-2 inhibitörlerinin (empagliflozin, dapagliflozin vb.) ve GLP-1 analoglarının (exenatid vb.) kardiyak etkilerine ilişkin olumlu sonuçlar veren geniş ...
Bahriye Gültaş, Soner Cander, Özen Öz Gül   +2 more
doaj   +1 more source

Tip 2 Diyabetli Hastalarda Dapagliflozin Tedavisinin Trombosit Fonksiyonları ve İnflamasyon Üzerine Etkisi

Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2019
Dapagliflozin kardiyovasküler hastalıklarda güvenli ve yararlı olduğu gösterilen bir oral anti-diyabetik (OAD) ilaçtır. Dapagliflozinin kardiyovasküler olumlu etkilerinin kesin mekanizması tam olarak bilinmemektedir.
Mehmet Ali Eren, Çiğdem Cindoğlu, Burcu Dikeç Gökçe, Ali Gökçe, Tevfik Sabuncu   +4 more
doaj   +1 more source

Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway

Biomolecules
Recently, the vascular protective effect of anti-diabetic agents has been receiving much attention. Sodium glucose cotransporter 2 (SGLT2) inhibitors had demonstrated reductions in cardiovascular (CV) events.
Li Han, Guoxin Ye, Wenjing Su, Yuankang Zhu, Wenqi Wu, Liangshi Hao, Jing Gao, Zhen Li, Fang Liu, Junli Duan   +9 more
doaj   +1 more source

Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study

BMC Cancer
Aim This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the ...
Huseyin Ali Ozturk, Mevlut Koc, Ramazan Azim Okyay, Dilan Damla Ozturk, Erdinc Gulumsek, Mahmut Buyuksimsek, Mehmet Turker, Abdullah Eren Cetin, Fatih Necip Arici, Hilmi Erdem Sumbul   +9 more
doaj   +1 more source

The Effect of Dapagliflozin on Absence Epilepsy in WAG/Rij Rats

Archives of Epilepsy
Objective: Epilepsy is the most common chronic brain disease that affects millions of people worldwide. In the present study, we investigated the effects of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which has been recently ...
Hatice Aygün
doaj   +1 more source

Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib

BMC Medicine
Background Sunitinib is an orally administered novel multi-targeted therapy for treating tumors especially for gastrointestinal stromal tumors and metastatic renal cell carcinoma (RCC) but associated with cardiovascular toxicity.
Shi-yu Huang, Min Hu, Yu-jie Chen, Jia-chen Liu, Zhi-yuan Yao, Zhi-yuan Chen, Xiu-heng Liu, Lei Wang   +7 more
doaj   +1 more source

Pharmacoeconomics of dapagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control

Качественная клиническая практика, 2018
Objectives. To evaluate the cost-effectiveness of dapagliflozin in combination with metformin in the treatment T2DM in comparison with glimepiride and sitagliptin also combined with metformin. Methods.
S. K. Zyryanov, M. F. Kalashnikova, D. Yu., E. V. Afanasyeva   +3 more
doaj